SECOND TRIMESTER SURGICAL TERMINATION OF PREGNANCY FOLLOWED BY AN UNUSUAL COMPLICATION AND WHY MEDICAL INDUCTION IS PREFERABLE WHENEVER POSSIBLE: CASE PRESENTATION

  • Claudia Mehedintu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Nicolae Malaxa” Clinical Hospital, Bucharest, Romania
  • Francesca Frîncu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & “Nicolae Malaxa” Clinical Hospital, Bucharest, Romania
  • Aida Petca “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • Mihai Dumitrașcu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • Diana Secară “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • Monica Cîrstoiu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • Andreea Carp-Velișcu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • Antoine Edu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & “Nicolae Malaxa” Clinical Hospital, Bucharest, Romania
  • Marina Rodica Antonovici Nicolae Malaxa Clinical Hospital
Keywords: medical abortion, mifepristone, misoprostol, in utero fetal demise

Abstract

Although induced abortion, either elective or medically justified, is one of the most common gynecologic procedures worldwide, only a small proportion of these procedures are performed in the second trimester of pregnancy (10–15%). 2nd trimester pregnancy termination (PT) may be realized via medical or surgical methods. Over the last decades, both medical and surgical PT methods have evolved and been intensively studied in regard to efficacy, safety and acceptability. From medical system and health insurance point of view medical abortion / induction of labor is preferable whenever possible, since the overall costs are less than that of surgical removal of the fetus (potential complication risks included). However, in regard to patient’s stress, the decision is debatable and should be made in accordance with the patient’s preferences, especially when the PT is not elective.

References

[1] P. A. Lohr, J. L. Hayes and K. Gemzell-Danielsson, “Surgical versus medical methods for second trimester induced abortion”, Cochrane Database Syst Rev, Jan, vol 23, no 1, CD006714, 2008.
[2] K. Lerma and K. A. Shaw, “Update on second trimester medical abortion”, Curr Opin Obstet Gynecol, vol 29, no 6, Dec, pp:413-418, 2017.
[3] S. E. Little, E. Janiak, D. Bartz and N. A. Smith, “Second trimester dilation and evacuation: a risk factor for preterm birth?”, J Perinatol, vol 35, no 12, Dec, pp:1006-1010, 2015.
[4] K. A. Shaw and K. Lerma, “Update on second-trimester surgical abortion”, Curr Opin Obstet Gynecol, vol 28, no 6, Dec, pp:510-516, 2016.
[5] E. Maistrellis, E. Janiak, R. Hammel, S. Hurwitz, L. Delli-Bovi and D. Bartz, “Demographic, Clinical, and Counseling Factors Associated with the Selection of Pregnancy Termination Method in the Second Trimester for Fetal and Pregnancy Anomalies”, Womens Health Issues, vol 29, no 4, Jul-Aug, pp:349-355, 2019.
[6] J. Cappiello, J. Merrell and D. Rentschler, “Women's experience of decision-making with medication abortion”, MCN Am J Matern Child Nurs, vol 39, no 5, Sep-Oct, pp:325-330, 2014.
[7] Y. Swica, E. Chong, T. Middleton, L. Prine, M. Gold, C. A. Schreiber, B. Winikoff, “Acceptability of home use of mifepristone for medical abortion”, Contraception, vol 88, no 1, Jul, pp:122-127, 2013.
[8] K. Z. Donnelly and R. Thompson, “Medical versus surgical methods of early abortion: protocol for a systematic review and environmental scan of patient decision aids”, BMJ Open, vol 5, no 7, Jul 14, e007966, 2015.
[9] H. Bracken, N. T. N. Ngoc, D. Q. Ha, N. R. Paredes, V. B. Quyet, N. T. H. Linh, M. A. Ortiz, M. Bousieguez and B. Winikoff, “Mifepristone pretreatment followed by misoprostol 200 mcg buccal for the medical management of intrauterine fetal death at 14-28 weeks: A randomized, placebo-controlled, double blind trial”, Contraception, vol 102, no 1, Jul, pp:7-12, 2020.
[10] E. R. Allanson, S. Copson, K. Spilsbury, S. Criddle, B. Jennings, D. A. Doherty, A. M. Wong and J. E. Dickinson, “Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial”, Obstet Gynecol, vol 137, no 5, May 1, pp:801-809, 2021.
[11] O. S. Tang, K. Gemzell-Danielsson and P. C. Ho, “Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects”, Int J Gynaecol Obstet, vol 99, Suppl 2, S160–S167, 2007.
[12] K. R. Meckstroth, A. K. Whitaker, S. Bertisch, et al, “Misoprostol administered by epithelial routes: Drug absorption and uterine response”, Obstet Gynecol, vol 108, no 3, pp:582–590, 2006.
[13] World Health Organization. Medical management of abortion. Geneva: World Health Organization; ISBN 978-92-4-155040-6, 2018.
[14] L. Schummers, E. K. Darling, S. Dunn, K. McGrail, A. Gayowsky, M. R. Law, T. L. Laba, J. Kaczorowski and W. V. Norman, “Abortion Safety and Use with Normally Prescribed Mifepristone in Canada”, N Engl J Med, Dec 8, 2021.
[15] M. L. Lie, S. C. Robson and C. R. May, “Experiences of abortion: a narrative review of qualitative studies”, BMC Health Serv Res, vol 8, Jul 17, p:150, 2008.
Published
2022-01-06
How to Cite
Mehedintu, C., Frîncu, F., Petca, A., Dumitrașcu, M., Secară, D., Cîrstoiu, M., Carp-Velișcu, A., Edu, A., & Antonovici, M. (2022). SECOND TRIMESTER SURGICAL TERMINATION OF PREGNANCY FOLLOWED BY AN UNUSUAL COMPLICATION AND WHY MEDICAL INDUCTION IS PREFERABLE WHENEVER POSSIBLE: CASE PRESENTATION. Romanian Journal of Clinical Research, 4(2). https://doi.org/10.33695/rjcr.v4i2.75